HK1173654A1 - 治療化合物及相關的使用方法 - Google Patents

治療化合物及相關的使用方法

Info

Publication number
HK1173654A1
HK1173654A1 HK13100713.1A HK13100713A HK1173654A1 HK 1173654 A1 HK1173654 A1 HK 1173654A1 HK 13100713 A HK13100713 A HK 13100713A HK 1173654 A1 HK1173654 A1 HK 1173654A1
Authority
HK
Hong Kong
Prior art keywords
related methods
therapeutic compounds
therapeutic
compounds
methods
Prior art date
Application number
HK13100713.1A
Other languages
English (en)
Inventor
征希 鈴木
見 近藤
宗明 栗村
．瓦爾盧魯
高橋　彰
武志 黑田
永 高橋
多惠 福島
伸 宮村
．高希
．道格拉
．哈裏曼
．埃爾德
聰 清水
．霍杰茨
．紐科姆
Original Assignee
大塚製藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226819&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1173654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 大塚製藥株式會社 filed Critical 大塚製藥株式會社
Publication of HK1173654A1 publication Critical patent/HK1173654A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HK13100713.1A 2009-12-31 2013-01-16 治療化合物及相關的使用方法 HK1173654A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29154409P 2009-12-31 2009-12-31
US29155409P 2009-12-31 2009-12-31
US29155009P 2009-12-31 2009-12-31
PCT/US2010/062555 WO2011082337A1 (en) 2009-12-31 2010-12-30 Therapeutic compounds and related methods of use

Publications (1)

Publication Number Publication Date
HK1173654A1 true HK1173654A1 (zh) 2013-05-24

Family

ID=44226819

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13100713.1A HK1173654A1 (zh) 2009-12-31 2013-01-16 治療化合物及相關的使用方法

Country Status (28)

Country Link
US (3) US9073890B2 (zh)
EP (2) EP3056207B1 (zh)
JP (3) JP5753194B2 (zh)
KR (1) KR20120115350A (zh)
CN (2) CN105218516A (zh)
AR (1) AR079814A1 (zh)
AU (2) AU2010339423C1 (zh)
BR (1) BR112012016392A2 (zh)
CA (1) CA2785923C (zh)
CO (1) CO6571895A2 (zh)
CY (1) CY1118249T1 (zh)
DK (1) DK2521549T3 (zh)
EA (2) EA028066B1 (zh)
ES (1) ES2598577T3 (zh)
HK (1) HK1173654A1 (zh)
HR (1) HRP20161330T1 (zh)
HU (1) HUE030752T2 (zh)
IL (1) IL219974A0 (zh)
LT (1) LT2521549T (zh)
MX (2) MX349476B (zh)
MY (1) MY161082A (zh)
PH (1) PH12015502823A1 (zh)
PL (1) PL2521549T3 (zh)
PT (1) PT2521549T (zh)
SG (2) SG181523A1 (zh)
SI (1) SI2521549T1 (zh)
TW (2) TWI591063B (zh)
WO (1) WO2011082337A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211973T1 (hr) 2009-09-03 2022-03-18 Bristol-Myers Squibb Company Kinazolini kao inhibitori ionskih kalijskih kanala
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
AR086798A1 (es) * 2011-06-29 2014-01-22 Otsuka Pharma Co Ltd Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
EP2729007A1 (de) * 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2013013614A1 (zh) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
BR112014030416A2 (pt) * 2012-06-07 2017-06-27 Hoffmann La Roche composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
PE20150228A1 (es) 2012-06-11 2015-02-19 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida
CN102702116B (zh) * 2012-06-13 2014-12-31 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
KR20150135359A (ko) 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
CN106831721B (zh) * 2013-10-16 2019-10-22 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
PT3089971T (pt) 2014-01-01 2020-09-03 Medivation Tech Llc Compostos e métodos de utilização
KR20170117023A (ko) * 2014-12-05 2017-10-20 서브라마니암 아난탄 생체 아민 수송 조절인자로서 헤테로환상 화합물
CA3081443A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
EP3380469B1 (en) * 2015-11-25 2022-03-16 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
JP7160688B2 (ja) * 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3555051A4 (en) 2016-12-13 2020-06-10 Beta Therapeutics Pty. Ltd. HEPARANASE INHIBITORS AND USE THEREOF
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813887A (zh) 2016-12-20 2023-03-21 罗曼治疗***股份公司 包含阿塞那平的透皮治疗***
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
US20220089609A1 (en) 2018-07-26 2022-03-24 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
WO2020132409A1 (en) * 2018-12-20 2020-06-25 Trustees Of Boston University Stk19 inhibitors for treatment of cancer
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
CN116096714A (zh) 2020-06-10 2023-05-09 安力高医药股份有限公司 用于治疗冠状病毒、小核糖核酸病毒和诺罗病毒感染的抗病毒化合物
WO2022140456A1 (en) 2020-12-22 2022-06-30 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
HN2002000067A (es) 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
JP2005526714A (ja) * 2002-01-17 2005-09-08 ニューロジェン・コーポレーション カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
AU2003300791A1 (en) * 2002-12-13 2004-07-09 Neurogen Corporation Combination therapy for the treatment of pain
WO2004055004A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
AU2004230928B2 (en) * 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EP1702077A4 (en) * 2003-12-08 2007-10-31 Pfizer INTERACTION OF THE NMDA RECEPTOR WITH THE TYROSINE PHOSPHATASE STEP PROTEIN IN PSYCHOTIC DISORDERS
ATE485824T1 (de) * 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
US20060128702A1 (en) 2004-11-23 2006-06-15 Manojit Pal Heterocyclic and bicyclic compounds, compositions and methods
JP2007084494A (ja) 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
JP2009519995A (ja) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体
EP1981525B1 (en) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
EP2021019A4 (en) 2006-05-15 2009-12-09 Senex Biotechnology Inc IDENTIFICATION OF CDKI PATH HAZARD
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008092862A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
AU2008231695B2 (en) 2007-03-28 2013-03-28 Novartis Ag Purinyl derivatives and their use as potassium channel modulators
CN101646669B (zh) 2007-03-28 2013-09-04 神经研究公司 嘌呤基衍生物及其作为钾通道调节剂的用途
WO2009000085A1 (en) 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
WO2009097446A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
EP2445346A4 (en) 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
WO2010151799A2 (en) 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
HRP20211973T1 (hr) 2009-09-03 2022-03-18 Bristol-Myers Squibb Company Kinazolini kao inhibitori ionskih kalijskih kanala
EP2496081B1 (en) 2009-11-02 2020-03-25 Ariagen, Inc. Ite for cancer intervention and eradication

Also Published As

Publication number Publication date
AR079814A1 (es) 2012-02-22
MX349476B (es) 2017-07-31
CN102883723B (zh) 2015-09-16
DK2521549T3 (en) 2016-11-14
KR20120115350A (ko) 2012-10-17
WO2011082337A1 (en) 2011-07-07
HUE030752T2 (en) 2017-05-29
AU2010339423A1 (en) 2012-06-14
US20130053341A1 (en) 2013-02-28
AU2010339423C1 (en) 2017-03-09
TW201630898A (zh) 2016-09-01
EA201790962A1 (ru) 2018-04-30
EP3056207B1 (en) 2018-06-20
TW201124395A (en) 2011-07-16
PT2521549T (pt) 2016-10-14
CN102883723A (zh) 2013-01-16
BR112012016392A2 (pt) 2017-10-03
IL219974A0 (en) 2012-07-31
PH12015502823A1 (en) 2018-01-22
EP3056207A1 (en) 2016-08-17
EP2521549A1 (en) 2012-11-14
TWI591063B (zh) 2017-07-11
US20150307477A1 (en) 2015-10-29
SG10201408789WA (en) 2015-02-27
SI2521549T1 (sl) 2017-01-31
JP2017071639A (ja) 2017-04-13
CA2785923A1 (en) 2011-07-07
JP5753194B2 (ja) 2015-07-22
CO6571895A2 (es) 2012-11-30
TWI601723B (zh) 2017-10-11
EA028066B1 (ru) 2017-10-31
JP2015178517A (ja) 2015-10-08
JP2013516428A (ja) 2013-05-13
WO2011082337A8 (en) 2012-07-05
LT2521549T (lt) 2016-11-10
US20170217923A1 (en) 2017-08-03
CY1118249T1 (el) 2017-06-28
AU2010339423B9 (en) 2016-12-22
US9073890B2 (en) 2015-07-07
ES2598577T3 (es) 2017-01-27
HRP20161330T1 (hr) 2016-12-30
JP6062999B2 (ja) 2017-01-18
SG181523A1 (en) 2012-07-30
CN105218516A (zh) 2016-01-06
PL2521549T3 (pl) 2017-01-31
CA2785923C (en) 2017-06-06
MX2012007727A (es) 2012-11-22
AU2010339423B2 (en) 2016-12-01
EA201290593A1 (ru) 2013-12-30
US9630947B2 (en) 2017-04-25
AU2017201175A1 (en) 2017-03-16
EP2521549B1 (en) 2016-08-17
MY161082A (en) 2017-04-14
EP2521549A4 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
HK1173654A1 (zh) 治療化合物及相關的使用方法
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
HK1211889A1 (zh) 二氨基吩噻嗪的治療用途
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201106730B (en) Methods of treatment using combination therapy
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
HK1149933A1 (zh) 二氮咔唑和其使用方法
IL209548A0 (en) Diazacarbazoles and methods of use
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
ZA201205057B (en) Fungicidal compounds and methods of their use
GB201011411D0 (en) Therapeutic compounds and their use
EP2406244A4 (en) ESTROGEN COMPOUNDS AND METHOD FOR THEIR USE
EP2440238A4 (en) Methods of Treatment
GB0913300D0 (en) Therapeutic compounds and their use
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法
GB201009614D0 (en) Therapeutic use of compounds
GB0809936D0 (en) Therapeutic use of zolpidem
GB0819854D0 (en) Therapeutic use of zolpidem
GB201019938D0 (en) Determination of therapeutic agents
GB201004480D0 (en) Therapeutic use of new compounds II

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201226